gliclazide has been researched along with irsogladine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishibashi, T; Ishikawa, K; Matsumoto, T; Sakurai, K; Tachibana, K; Tanaka, A; Yokote, K | 1 |
| Himi, T; Kakuki, T; Kohno, T; Kojima, T; Konno, T; Miyata, R; Nomura, K; Sawada, N; Takano, K | 1 |
2 other study(ies) available for gliclazide and irsogladine
| Article | Year |
|---|---|
The anti-ulcer agent, irsogladine, increases insulin secretion by MIN6 cells.
Topics: Animals; Anti-Ulcer Agents; Cell Line; Cell Membrane; Connexins; Cyclic AMP; Enzyme-Linked Immunosorbent Assay; Gap Junction delta-2 Protein; Gap Junctions; Glucose; Glycyrrhetinic Acid; Insulin; Insulin Secretion; Mice; Triazines; Up-Regulation | 2012 |
Irsogladine maleate regulates gap junctional intercellular communication-dependent epithelial barrier in human nasal epithelial cells.
Topics: Antineoplastic Agents; Cell Communication; Epithelial Cells; Gap Junctions; Gene Expression; Glycyrrhetinic Acid; Humans; Interleukin-8; Nasal Mucosa; Oleic Acids; Tight Junction Proteins; Triazines; Tumor Necrosis Factor-alpha | 2015 |